Medical Devices Europe

Europe Smart Insulin Pens Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Europe Smart Insulin Pens Market Industry Trends and Forecast to 2034: Segmented by (Type, Connectivity, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Europe · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $28.1 Mn Placeholder estimate
Estimate 2025 $32.9 Mn 18.1% of the global market
Projected 2034 $135.0 Mn 310.8% Adds $102.1 Mn over 9 forecast years
CAGR 2025–2034 17.0% Faster than 94% of 180 Medical Devices markets here
Key players 5
  • Europe is 18.15% of the global market.
  • Among regions, the largest is North America at $102.0 Mn.
  • Fastest growing: Africa at 19.9% a year.
  • Europe ranks 3rd of 6 by size among regions.

Market size projection

Europe

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$102.1 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Smart Insulin Pens Market market size by year, Europe
YearMarket sizeChange that yearSince 2025
2024 (estimate) $28.1 Mn — —
2025 (base) $32.9 Mn +$4.8 Mn —
2026 (forecast) $38.4 Mn +$5.6 Mn +17%
2027 (forecast) $45.0 Mn +$6.5 Mn +36.9%
2028 (forecast) $52.6 Mn +$7.6 Mn +60.2%
2029 (forecast) $61.6 Mn +$8.9 Mn +87.4%
2030 (forecast) $72.0 Mn +$10.5 Mn +119.2%
2031 (forecast) $84.3 Mn +$12.2 Mn +156.5%
2032 (forecast) $98.6 Mn +$14.3 Mn +200.1%
2033 (forecast) $115.4 Mn +$16.8 Mn +251.1%
2034 (forecast) $135.0 Mn +$19.6 Mn +310.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Europe Smart Insulin Pens Market Analysis at a glance
Market size, 2025$32.9 Mn placeholder estimate
Forecast, 2034$135.0 Mn placeholder estimate
Growth (CAGR), 2025–203417.0% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, connectivity and end user (see all)
Key playersNovo Nordisk A/S, Medtronic, Bigfoot Biomedical, Sanofi, Biocorp (see all)
Regulator in EuropeEU MDRSource: European Commission, medical devices. Checked 14 Nov 2026.
Active clinical trials1 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Europe Smart Insulin Pens Market Analysis Executive Summary

Smart insulin pens record each dose and send it to an app, helping people with diabetes track insulin and avoid missed or double doses.

Key segments of the smart Insulin Pens market include type (Reusable Smart Pens and Smart Pen Caps and Attachments) and connectivity (Bluetooth and NFC).

Bar chart: Europe Smart Insulin Pens market size, 2024–2034, placeholder estimates. $28.1 Mn in 2024, $32.9 Mn in 2025 and $135.0 Mn in 2034, 17.0% CAGR.
Europe Smart Insulin Pens market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Europe Smart Insulin Pens Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the smart Insulin Pens market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the smart Insulin Pens market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the smart Insulin Pens market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Smart Insulin Pens Market in Europe

The smart Insulin Pens market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Smart Insulin Pens Market in Europe

Smart Insulin Pens in Europe: rules, payment and research

In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first.⁠[1] In the countries we cover here, medical devices are regulated by ANSM (France)⁠[2], BfArM (Germany)⁠[3], Ministry of Health (Italy)⁠[4], Roszdravnadzor (Russia)⁠[5], AEMPS (Spain)⁠[6], MHRA (UK)⁠[7], IGJ (Netherlands)⁠[8], FAMHP (Belgium)⁠[9], Swissmedic (Switzerland)⁠[10], Läkemedelsverket (Sweden)⁠[11], Danish Medicines Agency (Denmark)⁠[12], URPL (Poland)⁠[13] and TITCK (Turkey)⁠[14]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.⁠[15] ClinicalTrials.gov lists 1 study on Smart Insulin Pens that is recruiting, active or about to start in Europe.⁠[16]

[1] European Commission, medical devices. Checked 14 Nov 2026.

[2] ANSM, French medicines agency. Checked 14 Nov 2026.

[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.

[4] Italian Ministry of Health. Checked 14 Nov 2026.

[5] Roszdravnadzor. Checked 14 Nov 2026.

[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.

[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[8] Health and Youth Care Inspectorate (IGJ). Checked 19 Nov 2026.

[9] Federal Agency for Medicines and Health Products (FAMHP). Checked 19 Nov 2026.

[10] Swissmedic. Checked 19 Nov 2026.

[11] Swedish Medical Products Agency (Läkemedelsverket). Checked 19 Nov 2026.

[12] Danish Medicines Agency. Checked 19 Nov 2026.

[13] Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). Checked 19 Nov 2026.

[14] Turkish Medicines and Medical Devices Agency (TITCK). Checked 19 Nov 2026.

[15] European Commission, health technology assessment. Checked 14 Nov 2026.

[16] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how smart Insulin Pens products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Europe.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Smart Insulin Pens right now, from free public sources.

Patients

Diabetes (adults), % of adults (WHO)
CountryValueYear
Belgium6.72022
Denmark2.32022
France2.72022
Germany6.62022
Italy7.22022
Netherlands6.42022
Poland10.82022
Russia8.12022
Spain3.62022
Sweden5.12022
Switzerland4.32022
Turkey16.62022
UK8.82022
Compare every country on the Public Health Dashboard

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Smart Insulin Pens in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Smart Insulin Pens market in Europe?
Placeholder estimate: about $32.9 Mn in 2025, rising to about $135.0 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Smart Insulin Pens market in Europe growing?
Placeholder estimate: about 17.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Smart Insulin Pens market report cover?
The report splits the market by type (Reusable Smart Pens, Smart Pen Caps and Attachments), connectivity (Bluetooth, NFC) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Smart Insulin Pens market?
Key players include Novo Nordisk A/S, Medtronic, Bigfoot Biomedical, Sanofi and Biocorp.
What is driving the Smart Insulin Pens market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the smart Insulin Pens market.
Who regulates Smart Insulin Pens in Europe?
In the EU, medical devices need CE marking under the Medical Device Regulation (MDR); for most devices, an independent notified body checks them first. Source: European Commission, medical devices. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on Smart Insulin Pens are running in Europe?
1 study is recruiting, active or about to start in Europe, counted across the 13 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on Smart Insulin Pens?
PubMed lists 43 papers on Smart Insulin Pens added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Europe

See all

Related on diabetes and remote monitoring and wearables

See the topic